Safety Study of Ivacaftor in Subjects With Cystic Fibrosis

NCT00457821 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: Ivacaftor 25 mg/75 mg
DRUG: Ivacaftor 75 mg/150 mg
DRUG: Ivacaftor 150 mg or 250 mg
DRUG: Placebo

Sponsor

Vertex Pharmaceuticals Incorporated

Collaborators

[object Object]